ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    idp 121
Previous Study | Return to List | Next Study

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02535871
Recruitment Status : Unknown
Verified September 2015 by Valeant Pharmaceuticals.
Recruitment status was:  Not yet recruiting
First Posted : August 31, 2015
Last Update Posted : September 14, 2015
Sponsor:
Information provided by (Responsible Party):
Valeant Pharmaceuticals

Brief Summary:
The primary objective of this study is to compare the efficacy, safety and tolerability of IDP-121 Lotion and vehicle in the treatment of subjects with acne vulgaris.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: IDP-121 Lotion Drug: IDP-121 Vehicle Lotion Phase 3

Detailed Description:
This is a multicenter, randomized, double-blind, parallel group, vehicle-controlled, 12-week study to evaluate relative changes in inflammatory and non-inflammatory lesion counts, as well as treatment success using an Evaluator's Global Severity Scale (EGSS) in subjects with moderate to severe acne. IDP-121 is a lotion for the topical treatment of acne.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
Study Start Date : September 2015
Estimated Primary Completion Date : July 2016
Estimated Study Completion Date : July 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne
U.S. FDA Resources

Arm Intervention/treatment
Experimental: IDP-121 Lotion
IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
Drug: IDP-121 Lotion
Investigational Product: IDP-121 Lotion
Placebo Comparator: IDP-121 Lotion Vehicle
IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
Drug: IDP-121 Vehicle Lotion
Comparator Product: IDP-121 Vehicle Lotion



Primary Outcome Measures :
  1. Absolute change in inflammatory lesion count from baseline to Week 12 [ Time Frame: 12 weeks ]

    At each visit the Evaluator will count the total number of inflammatory lesions (papules, pustules, and nodules) on the subject's face.

    Inflammatory lesions are defined as follows:

    Papule - a small, solid elevation less than 5 mm in diameter. Most of the lesion is above the surface of the skin.

    Pustule - a small, circumscribed elevation less than 5 mm in diameter that contains yellow-white exudate.

    Nodule - a subcutaneous lesion greater than or equal to 5 mm in diameter.


  2. Absolute change in non-inflammatory lesion count from baseline to Week 12 [ Time Frame: 12 weeks ]

    At each visit the Evaluator will count the total number of non-inflammatory lesions (open and closed comedones).

    Non-inflammatory lesions are defined as follows:

    Open comedones (black head) - a lesion in which the follicle opening is widely dilated with the contents protruding out onto the surface of the skin.

    Closed comedones (white head)- a lesion in which the follicle opening is closed, but the sebaceous gland is enlarged by the pressure of the sebum build up, which in turn causes the skin around the follicle to thin and become elevated with a white appearance.


  3. Proportion of subjects who have a least a 2 grade reduction at Week 12 from baseline in the Evaluator's Global Severity Score and were Clear or Almost Clear [ Time Frame: 12 weeks ]

    At each visit the severity will be determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris. Evaluations will be scored on a scale of 0-4 (Evaluator's Global Severity Score), with 0 being clear and 4 being severe. Please see below for complete definitions.

    0 - Clear - Normal, clear skin with no evidence of acne vulgaris

    1. Almost clear- Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red)
    2. Mild- Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only; no nodulo-cystic lesions)
    3. Moderate-Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, and there may or may not be one nodulo-cystic lesion
    4. Severe- Inflammatory lesions are more apparent, many comedones and papules/pustules, there may or may not be up to 2 nodulo-cystic lesions.


Secondary Outcome Measures :
  1. Percent change in inflammatory lesion count from baseline to Week 4, 8, and 12 [ Time Frame: 4, 8, and 12 weeks ]
    At each visit the Evaluator will count the total number of inflammatory lesions (papules, pustules, and nodules) on the subject's face, and the percent change will be calculated.

  2. Percent change in non-inflammatory lesion count from baseline to Week 4, 8, and 12 [ Time Frame: 4, 8, and 12 weeks ]
    At each visit the Evaluator will count the total number of non-inflammatory lesions (open and closed comedones), and the percent change will be calculated.

  3. Proportion of subjects who have a least a 2 grade reduction at Week 4, 8, and 12 from baseline in the Evaluator's Global Severity Score [ Time Frame: 4, 8, and 12 weeks ]

    At each visit the severity will be determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris. Evaluations will be scored on a scale of 0-4 (Evaluator's Global Severity Score), with 0 being clear and 4 being severe. Please see below for complete definitions.

    0 - Clear - Normal, clear skin with no evidence of acne vulgaris

    1. Almost clear- Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red)
    2. Mild- Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only; no nodulo-cystic lesions)
    3. Moderate-Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, and there may or may not be one nodulo-cystic lesion
    4. Severe- Inflammatory lesions are more apparent, many comedones and papules/pustules, there may or may not be up to 2 nodulo-cystic lesions.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   9 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female at least 9 years of age and older
  • Written and verbal informed consent must be obtained.
  • Subject must have a score moderate or severe on the Evaluator's Global Severity assessment at the screening and baseline visit
  • Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at the screening and baseline visits
  • Subjects must be willing to comply with study instructions and return to the clinic for required visits.

Exclusion Criteria:

  • Any dermatological conditions on the face that could interfere with clinical evaluations
  • Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive
  • Subjects with a facial beard or mustache that could interfere with the study assessments
  • Concomitant use of potentially irritating over-the-counter products

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02535871


Contacts
Contact: Anya Loncaric, MS 510-259-5284 aloncaric@solta.com

Sponsors and Collaborators
Valeant Pharmaceuticals
Investigators
Study Director: Anya Loncaric, MS Valeant Pharmaceuticals

Responsible Party: Valeant Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02535871     History of Changes
Other Study ID Numbers: V01-121A-302
First Posted: August 31, 2015    Key Record Dates
Last Update Posted: September 14, 2015
Last Verified: September 2015

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases